Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276598 | 0.88 | CNR1 (0.41) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL13437230 | 0.87 | KDM4E (0.44) | KDM4EMAPTALDH1A1L3MBTL1CNR1 | |
| SCHEMBL277227 | 0.80 | CNR1 (0.48) | KDM4EMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL24208982 | 0.76 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL277049 | 0.75 | CNR1 (0.57) | MAPTCNR1NPSR1CNR2 | |
| SCHEMBL13437233 | 0.75 | CNR1 (0.39) | MAPTALDH1A1CNR1PPARAGAA | |
| SCHEMBL25513993 | 0.74 | CNR2 (0.46) | KDM4ECNR1CNR2 | |
| SCHEMBL277180 | 0.73 | CNR1 (0.56) | MAPTCNR1NPSR1CNR2 | |
| SCHEMBL25513646 | 0.73 | CNR2 (0.47) | KDM4EHSD17B10CNR1CNR2 | |
| SCHEMBL13437232 | 0.72 | CNR1 (0.57) | MAPTCNR1NPSR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133904-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | JENRIN DISCOVERY, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8088798-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity | Jensen Discovery, Inc. | 2012-01-03 | — | — | US | disclosed |
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144791-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | KDM4E 1728/4885MAPT 4267/4885ALDH1A1 3407/4885 |
| US-20090069329-A1 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY | CNR2, CNR1, GPR119 | KDM4E 1728/4885MAPT 4267/4885ALDH1A1 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.